Drug Trial Radar · NCT04569747
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
393
Actual
Start
Jan 11, 2021
Primary completion
Mar 23, 2029
Study completion Sep 1, 2032
Sponsor
- Lead sponsor
- Dana-Farber Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Genentech, Inc.
- First posted
- Sep 30, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Conditions
- HER2-positive Breast Cancer
- Invasive Carcinoma of the Breast
- Breast Cancer
- Node Negative Breast Cancer
- Micrometastasis Breast Cancer
- Hormone Receptor Positive Breast Cancer
Interventions
Pertuzumab+TRASTUZUMABCombination product
Trastuzumab + pertuzumab SC FDC (PHESGO) will be administered on Day 1 of each 21-day cycle , subcutaneous, fixed dose
ADJUVANT ENDOCRINE THERAPYDrug
Oral, daily per cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease Free Survival at 3 YearsTime frame: 3 Years
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Stamford Hospital
Stamford, Connecticut
University of Miami- Sylvester Comprehensive Cancer Center
Miami, Florida
Winship Cancer Institute at Emory University Hospital Midtown
Atlanta, Georgia
Emory University - Winship Cancer Institute
Atlanta, Georgia
Winship Cancer Institute at Emory Saint Joseph's Hospital
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
Indiana University Health Schwarz Cancer Center
Indianapolis, Indiana
Indiana University Health - Melvin and Bren Simon Cancer Center
Indianapolis, Indiana
Indiana University Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana
Eastern Maine Medical Center (Northern Light)
Brewer, Maine
Dana Farber Cancer Institite
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber Brigham Cancer Center - Foxborough
Foxborough, Massachusetts
Cape Cod Healthcare Center
Hyannis, Massachusetts
Dana-Farber at Milford
Milford, Massachusetts
Dana-Farber at South Shore Hospital
Weymouth, Massachusetts
Dana-Farber Cancer Insitute at Londonderry Hospital
Londonderry, New Hampshire
New York University Langone Hospital -Brooklyn
Brooklyn, New York
New York University Langone Hospital - Long Island
Mineola, New York
New York University Langone Health
New York, New York
UNC Rex Hematology Oncology Associated - Cary
Cary, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
UNC Rex Hematology Oncology Associates of Garner
Garner, North Carolina
UNC Rex Cancer Center
Raleigh, North Carolina
UNC Rex Cancer Center at Wakefield
Raleigh, North Carolina
The Christ Hospital
Cincinnati, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Greco-Hainsworth Centers for Research/Tennessee Oncology
Nashville, Tennessee
SCRI Oncology Partners
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
Baylor College of Medicine Medical Center
Houston, Texas
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.